Over the past two decades, in response to mounting failures, clinical trials of disease-modifying therapies (DMTs) in Alzheimer’s disease (AD) have progressively moved earlier in the disease spectrum to increase the probability of success; today, most Phase III clinical trials enroll patients with “early AD,” commonly comprising mild cognitive impairment (MCI) due to AD (a.k.a. prodromal AD) and mild AD dementia (e.g., MMSE scores ≥ 22). Given the increasing awareness and sensitivity about earlier diagnosis and management of the disease, it is essential to understand how neurologists perceive the performance of current therapies in early patients, especially their expectations for an emerging DMT for early AD on key clinical and nonclinical attributes.

Questions Answered

  • What are the treatment drivers and goals for early AD?
  • Which attributes are key influencers, which have limited impact, and which are hidden opportunities?
  • How do current therapies perform on key treatment drivers and goals for early AD?
  • What are the prevailing areas of unmet need and opportunity in early AD?
  • Based on a conjoint analysis and TPP simulation, what trade-offs between efficacy, safety, and price are neurologists willing to make for a hypothetical new drug for early AD?

Markets covered: United States, United Kingdom, France, and Germany.

Primary Research: Survey of 60 U.S. neurologists and 30 European neurologists.

Key Drugs Covered: donepezil, galantamine, rivastigmine patch, memantine, Namzaric, gantenerumab, BAN2401, elenbecestat.

Key metrics included:

  • Target Product Profile (TPP) simulator based on conjoint analysis methodology.
  • Stated vs. derived importance of product attributes on prescribing behavior.
  • Assessment of current drug performance against treatment drivers and goals.
  • Physician perceptions of unmet needs in the indication and related indications.
  • Analysis of remaining drug development opportunities.

Product Description

Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. Two market scenarios are profiled in detail by DRG experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.

Table of contents

  • Alzheimer's Disease - Unmet Need - Detailed, Expanded Analysis (US&EU) Early Alzheimer's Disease

Author(s): Ruchita Kumar, Ph.D

Ruchita has joined as a Lead Analyst in the Central Nervous System and Ophthalmology team at Decision Resources Group.

She comes with eight years of experience in handling various types of commercial assessment projects. She has worked on variety of opportunity assessment and market intelligence projects involving preparation of disease narratives, epi-based forecasts, patent landscapes, social media analysis and building brand performance reports across different therapy areas. She earned a Ph.D. in design and development of modified release dosage forms of anti-diabetic drugs from the University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh.


Related Reports

Alzheimer's Disease - Landscape & Forecast - Disease Landscape & Forecast

The Alzheimer’s disease (AD) market comprises a handful of symptomatic options that offer modest efficacy for a limited duration, leaving wide open th...

View Details

Alzheimer's Disease - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)

For the estimated 3.4 million people in the United States with Alzheimer’s disease (AD), approved pharmacotherapy is limited to four procognitive symptomatic agents (e.g., donepezil, memantin...

View Details

Alzheimer's Disease | Disease Landscape and Forecast | G7 | 2019

The Alzheimer’s disease (AD) market comprises a handful of symptomatic options that offer modest efficacy for a limited duration, leaving wide open the oppo...

View Details